Novo Nordisk to Lower U.S. List Prices for Wegovy, Ozempic and Rybelsus in 2027

Novo Nordisk has announced a major reduction in the U.S. list prices of three widely used semaglutide medicines: Wegovy, Ozempic and Rybelsus. Beginning January 1, 2027, the new wholesale acquisition cost, or list price, for all doses of these medications will be $675 per month.

“Our actions today answer that call and remove cost barriers so the value of Wegovy and Ozempic can be realized by more patients,” Jamey Millar, executive vice president, U.S. operations of Novo Nordisk, said in a statement. “The lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or coinsurance benefit designs.”

According to the company, this represents an approximate 50% reduction in the current list price for Wegovy and about a 35% reduction for Ozempic. The price change applies to all available doses of the medications in the United States.

Importantly, this reduction affects the official list price (the price used as a reference point in the health care system) and may particularly benefit patients whose out-of-pocket costs are tied directly to list price. This can include individuals with high-deductible insurance plans, coinsurance based on list price or certain coverage gaps.

Novo Nordisk stated that the change does not affect its existing direct-to-patient self-pay pricing programs. In recent years, the company has introduced multiple initiatives aimed at expanding access to semaglutide medicines. These efforts include savings offers, partnerships with select telehealth providers and access through NovoCare Pharmacy for self-pay patients.

Semaglutide is the active ingredient in all three medications. While they are part of the GLP-1 receptor agonist class, Novo Nordisk emphasized that not all GLP-1 medicines are the same. These semaglutide products have multiple U.S. Food and Drug Administration-approved indications across obesity, Type 2 diabetes, chronic kidney disease and cardiovascular risk reduction.

Wegovy is approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It is also approved to reduce the risk of major cardiovascular events, such as heart attack, stroke or death, in adults with known heart disease and obesity or overweight. Ozempic is approved for Type 2 diabetes and to reduce cardiovascular risk in certain patients, and it also carries an indication related to chronic kidney disease in adults with Type 2 diabetes. Rybelsus is an oral semaglutide approved for Type 2 diabetes.

The company says the list price reduction reflects ongoing efforts to improve affordability and navigate the complexities of the evolving U.S. health care system. For patients, the impact will depend on their individual insurance coverage, deductible structure and pharmacy benefit design. However, for many whose costs are directly linked to list price, this announcement may represent meaningful savings beginning in 2027.

“Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with Type 2 diabetes in the United States,” said Millar. “Private and public payers, as well as patients, want access and have been calling for lower list prices.”